Jun Zhou1,*, Eddie Guo2, Senia Ma2, Hok Shing Li3, Kai Jia4
1Wuhan Zhi School Culture and Media Co., Ltd., Wuhan, Hubei, China.
2Beijing Qingmiao International Bilingual School, Beijing, China.
3Pennsylvania State University, Pennsylvania, PA, USA.
4Schveya (Tianjin) Pharmaceutical Co., Ltd., Tianjin, China.
*Corresponding author: Jun Zhou
References
[1] A N D S, A V R B, B S P, et al. ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma – ScienceDirect [J]. Journal of Controlled Release, 2021, 31(8):19-29.
[2] Yang J, Yao Y, Tong L, et al. CD47 is highly expressed in gliomas and targeting CD47 is a promising therapeutic strategy [J]. European Journal of Inflammation, 2021, 19(2): 213-234.
[3] Minns H E, Oscar P, Hong-Jian W, et al. DIPG-45. Radiation induces a robust interferon response in Diffuse Midline Glioma (DMG), improving the potential for combination immunotherapy [J]. Neuro-Oncology, 2022, 19(11): 612-620.
[4] Wang M H, Kim A, Ruschin M E, et al. Dosimetric Comparison in Malignant Glioma Patients Clinically Treated on Hybrid Magnetic Resonance Imaging (MRI)-Linac (MRL) vs. Conventional Linac [J]. International Journal of Radiation Oncology, Biology, Physics, 2021, 29(3):117-125.
[5] Calabrese E, Villanueva-Meyer J, Rudie J, et al. The University of California San Francisco Preoperative Diffuse Glioma (UCSF-PDGM) MRI Dataset [J]. Radiol Artif Intell., 2021. 35(4): 186-189.
[6] Wang H, Tan C, Xu T, et al. Rapid progression of an IDH-wild type histological low-grade glioma harbouring TERT promoter mutation and diffuse CD34 expression: a case report [J]. Termedia, 2021, 18(1): 347-348.
[7] Jiang L, Lin C, Song L, et al. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappa B/I kappa B alpha negative feedback loop (vol 122, pg 33, 2012) [J]. The Journal of Clinical Investigation: The Official Journal of the American Society for Clinical Investigation, 2021, 29(12):131-137.
[8] Wang Y, Zhao D, Wang H B, et al. Long non-coding RNA-LINC00941 promotes the proliferation and invasiveness of glioma cells [J]. Neuroscience letters, 2022, 79(10): 1369-1374.
[9] Zhang P, Wang G M, Zhou F, et al. MicroRNA-1592 in the Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Inhibits the Glioma Development In Vivo and In Vitro [J]. Journal of Biomaterials and Tissue Engineering, 2022, 19(4): 82-87.
[10] Sheybani N D., Breza V R., Paul S, et al. ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma [J]. Journal of Controlled Release, 2021, 33(3): 192-197.
[11] Zhou Y, Guo Y X, Chen L F, et al. Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy [J]. Theranostics, 2022, 12(02): 325-328.
[12] Chen J J, Dai Q, Yang Q Y, et al. Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma [J]. Journal of Nanobiotechnology, 2022, 20(1): 2619-2624.
[13] Lara C, Janssens G O, Stephanie B, et al. DIPG-24. Neurological symptom improvement after re-irradiation in patients with dif-fuse intrinsic pontine glioma (DIPG): A retrospective analysis of the SIOP-E-HGG/DIPG project [J]. Neuro-Oncology, 2022, 13(5): 714-718.
[14] Divya S, Suresh L P, John A. Enhanced deep-joint segmentation with deep learning networks of glioma tumor for multi-grade classification using MR images [J]. Pattern analysis and applications: PAA, 2022, 16(5): 254-259.
[15] Jessica B, Diana C, Ketty K, et al. IMG-09. Characterisation of a panel of in vivo models of paediatric-type diffuse high-grade glioma (PDHGG) using magnetic resonance imaging [J]. Neuro-Oncology, 2022, 17(8): 336-341.
[16] Umemura Y, Orringer D, Junck L, et al. Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial [J]. 2023, 22(5): 921-926.
[17] Chi S, Zhang L, Cheng H, et al. Biomimetic Nanocomposites Camouflaged with Hybrid Cell Membranes for Accurate Therapy of Early-Stage Glioma [J]. Angewandte Chemie, 2023, 24(8): 176-179.
[18] Jessica M, Santhana K K, Levi K, et al. TBIO-08. The molecular basis for rational targeting of FGFR-driven growth and invasiveness in pediatric brain tumors [J]. Neuro-Oncology, 2022, 25(11): 622-627.